GLPwatch
Papers (10389)
Page 142 of 174, ranked by citation count.
- [For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?]
- Reassessing retinopathy risk with tirzepatide therapy.
- Tirzepatide as adjunct to insulin for the treatment of type 1 diabetes.
- Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial.
- [Efficacy and safety of IdegLira for the intensification of type 2 diabetes treatment].
- Liraglutide Inhibits Autophagy to Ameliorate Post-Cardiac Arrest Brain Injury and Ferroptosis in Rats.
- Liraglutide for patients with non-alcoholic steatohepatitis.
- Comparison of the cardioprotective effects of liraglutide, dapagliflozin and their combination in a rat model of diabetes induced by streptozotocin.
- [Lixisenatide (Lyxumia), subcutaneous].
- Integrating incretin-based therapy into type 2 diabetes management.
- Incretins (GLP-1 Receptor Agonists) and Polycystic Ovaries.
- Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.
- Ethical Considerations in the Use of Weight Loss Medications.
- Exendin-4 increases the firing activity of hippocampal CA1 neurons through TRPC4/5 channels.
- Re-evaluating GLP-1 receptor agonist-associated changes in copeptin.
- Once-Weekly Mazdutide in Obesity or Overweight. Reply.
- More on Semaglutide in Early Type 1 Diabetes.
- Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes: A post-hoc analysis from a randomised trial.
- The Antidiabetic Armamentarium: Reducing the Residual Cardiovascular Risk with HbA<sub>1c(v)</sub>-Lowering Medications : Editorial to: "GLP-1 Receptor Agonists and Cardiovascular Disease: A Meta-Analysis of Recent Cardiac Outcome Trials" by Jia X, Alam M, Ye Y et al.
- Influence of Hydrophobic Ion Pairing on Formulation Performance of Liraglutide in PLGA Microspheres.
- Which Drug Will "Lead" in Reducing Cardiac Events Among Heart Failure Patients With Diabetes?
- Tirzepatide for type 2 diabetes.
- Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?
- Endocrinology: What You May Have Missed in 2025.
- [The GLP-1 analogue battle: effects of semaglutide 0,5 mg/weekly versus liraglutide 3 mg/daily on anthropometric parameters after 3 months in a real world-scenario].
- In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.
- Short- and long-acting GLP-1 receptor agonists decrease female sexual behaviors in experienced rodents.
- Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
- Sixty seconds on . . . semaglutide.
- [Natriuretic effect of exenatide: high efficacy and site of action].
- When the Transition Goes Wrong: A Rare Case of Diabetic Ketoalkalosis After Transitioning to Tirzepatide in Insulin-dependent Type 2 Diabetes.
- Erratum. Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2020;43:1813-1821.
- Tirzepatide Outperforms Dulaglutide for Type 2 Diabetes Control.
- [Effects of antidiabetic medications on metabolic-associated fatty liver disease].
- Positron emission tomography to assess drug occupancy at peripheral and central incretin receptors.
- In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin.
- Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes.
- Comparison of Exendin-4 and Its Single Amino Acid Substitutions as Parent Peptides for GLP-1 Receptor Imaging Probes.
- Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data.
- Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? Insights from post-hoc analysis of EXSCEL.
- Glucagon-like Peptide-1 receptor agonist use is not associated with increased reoperation risk following rotator cuff repair.
- Formulation and characterization of exenatide-loaded PLGA microspheres prepared by coacervation.
- Top studies of 2023 relevant to primary care: From the PEER team.
- Exploring Dietary Intake in Adults with Type 2 Diabetes Using GLP-1 Receptor Agonists: A Cross-Sectional Analysis.
- Weight management medications for chronic use in 37 veterans affairs medical centers-A medication use evaluation.
- ADDITION OF DULAGLUTIDE FOR A HIGH-DOSE INSULIN REQUIRING PATIENT WITH TYPE 2 DIABETES MELLITUS: A REMARKABLE RESPONSE.
- Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1.
- Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists.
- GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies.
- Liraglutide Ameliorates Gamma Radiation-Induced Hepatic Damage in Rats: The Role of an Autophagy Flux Activation via LKB1/AMPK/mTOR Axis.
- Liraglutide Plus Dapagliflozin for High Uric Acid and Microalbuminuria in Diabetes Mellitus Complicated With Metabolic Syndrome.
- Prospective, Matched Case-Control Study of Endoscopic Sleeve Gastroplasty and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease at One Year.
- GLP-1 and GIP Changes after Sleeve Gastrectomy and Weight Regain in Adolescents. Do we need a Boost?
- [Effect of exendin-4 on monocyte chemoattractant protein-1 expression in cultured rat glomerular mesangial cells induced by tumor necrosis factor-α in vitro].
- The Role of Race and Ethnicity in the Response to Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment: A Review.
- Efficacy and Safety of Dulaglutide in Type 2 Diabetes Patients in Endocrinology Clinics of Islamabad, Pakistan.
- Once-Weekly Tirzepatide Versus Once-Daily Basal Insulin in Managing Type 2 Diabetes Inadequately Controlled With Oral anti-Hyperglycemic Drugs: A Systematic Review and Meta-Analysis.
- [Type 2 diabetes mellitus and obesity: should we treat the obesity or the diabetes?].
- Dulaglutide markedly prevents peritoneal fibrosis in a rodent model of chronic kidney disease: Insights into the pathogenesis.
- iGlarLixi: A titrateable fixed-ratio combination of basal insulin + GLP-1 receptor agonist-An effective type 2 diabetes treatment option in China.